Fruzaqla (Fruquintinib) Patent Expiration, LOE Window & CMS Spending
Fruzaqla (Fruquintinib) by Takeda: FDA Orange Book core substance LOE 2035-09-07, 0 AB generics, $162.0M 2024 CMS Part D & Medicaid spend, and $25,200 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N217564 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2035-09-07 |
| Last Listed Patent or Exclusivity Date | 2035-09-07 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $162.0M |
| 2024 Medicare Part D Spend | $137.5M |
| 2024 Medicaid Spend | $24.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($25,200 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.